LOBEFLOBE SCIENCES LTD.

About LOBE SCIENCES LTD. (LOBEF)

LOBE SCIENCES LTD. (LOBEF) is a Biotechnology company headquartered in Vancouver, BC, Canada whose shares trade over-the-counter on the OTCQB tier.

Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally.

Products and services

Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally.

LOBEF key facts

Ticker symbol

LOBEF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Vancouver, BC, Canada

Country of incorporation

CA

Year of incorporation

2010

Estimated market cap

$4.34M (as of Apr 10, 2025)

Shares outstanding

183,238,792

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

8/31

Latest filing

Interim Financial Report (Nov 30, 2024)

LOBE SCIENCES LTD. leadership

• Frederick Sancilio — CEO
• Mathew Lee — CFO
• Maghsoud Dariani — CSO

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with L